Therapy for Benign Prostatic Hyperplasia

A phase III multi-center clinical study has demonstrated that a transurethral microwave thermotherapy system treats symptoms of benign prostatic hyperplasia (BPH) with minimal side effects and excellent patient tolerance.

BPH afflicts more than 50% of men by age 60 and as many as 90% by age 70 or 80. Treatment alternatives are limited and pose significant side effects, says Thermatrx, Inc. (Salt Lake City, UT, USA), which developed the new microwave system. Other advantages are a patient-friendly profile and ease-of-use in a doctor's office. Called TMx-2000, the system was recently cleared by the U.S. Food and Drug Administration (FDA). Thermatrx was formed in 1997 by BSD Medical Corp.and other partners to focus on the minimally invasive treatment of noncancerous urologic diseases.

"Microwave thermotherapy is an excellent therapy that has suffered from some missteps in the marketplace to date,” noted Hyrum A. Mead, president of BSD Medical. "We believe Thermatrx has addressed the problems associated with the current microwave thermotherapy systems and is nicely positioned to be the dominant player in this market.”




Related Links:
BSD Medical
Thermatrx